Study of ABT-888 in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Refractory Myeloma
Status:
Completed
Trial end date:
2015-02-10
Target enrollment:
Participant gender:
Summary
The combination of PARP inhibitor (ABT-888) with a proteasome inhibitors (bortezomib) have
demonstrated significant anti-myeloma effects in preclinical lab and animal studies. The goal
of this phase I trial is to evaluate in patients with relapsed or refractory multiple myeloma
the safety, toxicity profile and tolerability of ABT-888 (Veliparib) administered on a
schedule including twice daily oral dosing for 14 days followed by 1 week rest in combination
with standard dosing of Bortezomib.
Phase:
Phase 1
Details
Lead Sponsor:
AHS Cancer Control Alberta Alberta Health Services